Lutetium oxodotreotide ( 177 Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Table 2 Utilities and costs associated with adverse events

Adverse event (grade 3–4)	Utility decrement	Reference	Cost, GBP	Reference
Nausea	0.05	[22]	1.00	Assumed^b
Vomiting	0.05	[22]	1.00	Assumed^b
Diarrhea	0.05	[22]	1.00	Assumed^b
Abdominal pain	0.07	[23]	1.00	Assumed^b
Thrombocytopenia	0.11	[24]	84.22	[25]
Lymphopenia	0.11	Assumed^a	1.00	[26]
Leukopenia	0.11	Assumed^a	160.66	[28]
Stomatitis	0.11	Assumed^a	385.17	[27]
Fatigue	0.20	[20]	1.00	Assumed^b
Infections	0.11	Assumed^a	385.17	Assumed^c
Asthenia	0.20	Assumed^a	1.00	Assumed^b
Anemia	0.12	[20]	375.00	[28]
Pyrexia	0.11	Assumed^a	32.60	[27]
Hyperglycemia	0.11	Assumed^a	385.17	Assumed^c
Neutropenia	0.09	[22]	160.66	[28]
Hypertension	0.11	Assumed^a	16.34	[27]
Musculoskeletal pain	0.11	Assumed^a	385.17	Assumed^c
Flushing	0.11	Assumed^a	1.00	Assumed^b
Decreased appetite	0.20	Assumed equal to fatigue	1.00	Assumed^b

^aAssumed to be equal to worst disutility in line with NICE TA306 [21]
^bAssumed, does not have a notable impact on NHS resources at a national level, therefore assumed to be GBP 1.00
^cNo specific data available; assumed to be equal to the highest adverse event cost

ISSN: 1471-2407